What is MOMA?
The MOMA study aims at comparing two different approaches in maintenance therapy after an initial treatment with FOLFOXIRI + BEVACIZUMAB in patients with metastatic colorectal cancer. The use of the anti-angiogenic drug bevacizumab alone (that acts by blocking the growth of new blood vessels) will be compared with the use of the same drug in combination with metronomic chemotherapy, which consists in the flat administration of small doses of chemotherapy[…]
What is MACBETH?
The MACBETH study is designed for patients with metastatic colorectal cancer whose tumors do not bear mutations in the RAS and BRAF genes, have not received prior treatment for their metastatic disease and whose disease is considered surgically unresectable.
What is CRICKET?
The CRICKET study (Cetuximab rechallenge in irinotecan-pretreated mCRC, KRAS, NRAS and BRAF wild-type treated in 1st line with anti-EGFR Therapy) is designed for patients with metastatic colorectal cancer who have already received two lines of treatment. It aims at analyzing the activity of the rechallenge with the biologic agent cetuximab in the third line of treatment.
What is TRIBE2?
TRIBE2 is a randomized phase III trial comparing first-line treatment with FOLFOXIRI / bevacizumab followed by the reintroduction of FOLFOXIRI / bevacizumab after progression with a standard strategy including first-line FOLFOX / bevacizumab followed by FOLFIRI / bevacizumab after progression in patients with metastatic colorectal cancer.
What is INTERCEPTOR?
The INTERCPETOR study (Induction Chemotherapy Followed by cetuximab plus radiotherapy versus definitive radiation plus cisplatin) is a study designed for patients with locally advanced squamous cell carcinoma of the head and neck. It is a phase III study that aims at determining whether the use of the biologic drug cetuximab in combination with radiotherapy following induction chemotherapy is better than the standard combination of chemo- and radiotherapy in terms of overall survival.
What is PANDA?
PANDA is a randomized phase II trial designed for patients with metastatic colorectal cancer and an age higher than 70 years, whose tumors do not harbor mutations in RAS and BRAF genes. The study aims at investigating two treatment strategies with different intensities of chemotherapy, both in combination with the molecularly targeted drug panitumumab.
What is GIP2?
GIP-2 is a randomized phase III trial designed for patients – not previously treated- radically operated due to pancreatic cancer. The study is designed to compare two different regimens of “adjuvant chemotherapy”, i.e. two different post-operative treatments, administered with the aim of reducing the probability of disease relapse. Local recurrence or distant relapse are in fact possible after radical surgery due to the presence of micrometastases, i.e. small groups of cells that even the most sensitive imaging techniques cannot recognize, and post-operative treatments may help in reducing this probability.